Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prognosis and Clinicopathological Characters of Adult TFEB-Altered Renal Cell Carcinoma: A Single Center Experience of 18 Cases.

Autor: Wu J; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Cao CZ; Department of Urology, China-Japan Friendship Hospital, Beijing, China., Cui HL; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Du G; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Shi HZ; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Liang J; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Guo L; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Wang YC; Department of Imaging, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zhang J; Department of Imaging, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zhou AP; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Li CL; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zheng S; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: zhengshan@cicams.ac.cn., Shou JZ; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: shoujianzhong@cicams.ac.cn.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Apr; Vol. 22 (2), pp. 261-268.e3. Date of Electronic Publication: 2023 Nov 28.

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

Autor: Yan XQ; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing., Ye MJ; Department of Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha., Zou Q; Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing., Chen P; Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi., He ZS; Department of Urology, First Hospital of Peking University, Beijing., Wu B; Department of Urology, Shengjing Hospital of China Medical University, Shenyang., He DL; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an., He CH; Department of Urology, Cancer Hospital of Henan Province, Zhengzhou., Xue XY; Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou., Ji ZG; Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing., Chen H; Department of Urology, Harbin Medical University Cancer Hospital, Harbin., Zhang S; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu., Liu YP; Department of Oncology, The First Hospital of China Medical University, Shenyang., Zhang XD; Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing., Fu C; Department of Urology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang., Xu DF; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai., Qiu MX; Department of Urology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu., Lv JJ; Department of Urology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan., Huang J; Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou., Ren XB; Department of Immunology and Biotherapy, Cancer Institute & Hospital, Tianjin Medical University, Tianjin., Cheng Y; Department of Medical Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun., Qin WJ; Department of Urology, Xijing Hospital of Air Force Military Medical University, Xi'an., Zhang X; Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing., Zhou FJ; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou., Ma LL; Department of Urology, Peking University Third Hospital, Beijing., Guo JM; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai., Ding DG; Department of Urology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou., Wei SZ; Department of Urology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan., He Y; Department of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing., Guo HQ; Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing., Shi BK; Department of Urology, Qilu Hospital of Shandong University, Jinan., Liu L; Department of Urology, Qilu Hospital of Shandong University, Jinan., Liu F; Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou., Hu ZQ; Department of Urology, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan., Jin XM; Department of Oncology, General Hospital of Ningxia Medical University, Yinchuan., Yang L; Department of Urology, The Second Hospital of Lanzhou University, Lanzhou., Zhu SX; Department of Urology, Fujian Medical University Union Hospital, Fuzhou., Liu JH; Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming., Huang YH; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou., Xu T; Department of Urology, Peking University People's Hospital, Beijing., Liu B; Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou., Sun T; Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang., Wang ZJ; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing., Jiang HW; Department of Urology, Huashan Hospital, Fudan University, Shanghai., Yu DX; Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei., Zhou AP; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing., Jiang J; Department of Urology, The PLA General Hospital Army Characteristic Medical Center, Chongqing., Luan GD; Shanghai Junshi Biosciences Co., Ltd., Shanghai., Jin CL; Shanghai Junshi Biosciences Co., Ltd., Shanghai., Xu J; Shanghai Junshi Biosciences Co., Ltd., Shanghai., Hu JX; Shanghai Junshi Biosciences Co., Ltd., Shanghai., Huang YR; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing., Zhai W; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: jacky_zw2002@hotmail.com., Sheng XN; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing. Electronic address: doctor_sheng@126.com.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Feb; Vol. 35 (2), pp. 190-199. Date of Electronic Publication: 2023 Oct 21.

[Clinical tolerability and pharmacokinetics of troxacitabine].

Autor: Song Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China., Cui CX; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China., Zhang W; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China., Sun YK; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China., Yang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China., Zhou H; Beijing HebaBiz Biotechnology Co. Ltd/National and Region joint Engineering Center for Anticancer Drug Development, Beijing 102206, China., Liu HF; Beijing HebaBiz Biotechnology Co. Ltd/National and Region joint Engineering Center for Anticancer Drug Development, Beijing 102206, China., Zhou AP; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Publikováno v: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Jun 23; Vol. 45 (6), pp. 519-524.